about
Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides.The involvement of microRNAs in neurodegenerative diseasesNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugsIdentification and Characterization of the V(D)J Recombination Activating Gene 1 in Long-Term Memory of Context Fear Conditioning.Recent Developments in Peptide-Based Nucleic Acid DeliveryDesign of a small molecule against an oncogenic noncoding RNATrafficking through the Rev/RRE pathway is essential for efficient inhibition of human immunodeficiency virus type 1 by an antisense RNA derived from the envelope gene.Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.Synthesis and gene silencing properties of siRNAs containing terminal amide linkages.Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements.Stimulation of ribosomal frameshifting by antisense LNAAllele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.Lipid-induced insulin resistance: unravelling the mechanism.Layer-by-layer assembled antisense DNA microsponge particles for efficient delivery of cancer therapeutics.A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.Antisense oligonucleotide therapy for neurodegenerative disease.Selective enhancement of nucleases by polyvalent DNA-functionalized gold nanoparticles.Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotidesAntisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cellsInhibition of porcine reproductive and respiratory syndrome virus replication in vitro using DNA-based short antisense oligonucleotides.Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategiesDiacylglycerol activation of protein kinase Cε and hepatic insulin resistance.Natural and engineered nucleic acids as tools to explore biology.Epigenetic manipulation of gene expression: a toolkit for cell biologistsAntisense oligonucleotides as therapeutics for hyperlipidaemias.Coxsackievirus-induced myocarditis: new trends in treatment.Treatment strategies for acromegaly.Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.Artificial ribonucleases.A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and HumansAntisense oligonucleotides: from design to therapeutic application.Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansIntracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis.A covalently stabilized lipid-polycation-DNA (sLPD) vector for antisense oligonucleotide deliveryEffects of local mRNA structure on posttranscriptional gene silencing.Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies.Genetic modification of stem cells for transplantation.Small-molecule-mediated cleavage of RNA in living cells.RNA as a versatile and powerful platform for engineering genetic regulatory tools.
P2860
Q24816124-24A6A2AA-DB61-4DA6-AB3A-36FC6E764243Q26858788-B835098A-566E-4D32-8689-FA47F5B2F41EQ26863369-687817C1-AA12-45EA-9144-8C9EA5FAB742Q27314742-A7E783D2-60EA-440A-878D-C37C7E626B19Q27487857-3C1F8C20-908C-4FD6-A517-3C2249CF00D0Q28829505-F1AF4C56-37D3-49F1-BAFA-47EA438E4119Q30439325-E8217C82-234F-47D9-B18E-06B772F2B3D5Q33269609-1F6964EA-DDFA-4129-97B0-E033004BEF4BQ33358371-7FF4A985-775B-4A0C-9C90-1FF91F869FB3Q33980928-88ED8450-88BB-48C8-981F-CD9841D5624EQ34023372-906583E4-4026-4AFD-A51B-BC8DAD6EC4DCQ34348297-625B1402-07E3-46E5-87F6-E63EEBA5578DQ34370958-472A8FA2-F6DB-4C7E-A5F8-D3D529B7B07FQ34419904-478DE7B6-2D4C-40DD-9B67-6324B1118E1AQ34521106-46638CCB-B984-40C2-96FA-8EEFEF19BCD0Q34706913-2851647B-AA85-4A0C-A712-AE08AD8B50E0Q34830633-3CCFA16F-F7AE-4783-AC16-00B4C9424E23Q34846505-6B579484-EF53-4DF4-9F18-57F8ACE0F615Q34879217-978CA290-4B7C-475E-B8F4-F2CADDEA9223Q34881433-F748A0D2-C000-4AF5-B594-68082F5AAE9EQ35743375-9FD22128-DDA7-4460-B504-173790DC5704Q35884548-C6A7B2A2-E861-4C4F-AF17-1E1040EDE60DQ35964800-BAC661F1-3246-4E6C-B572-A091D90670F1Q35986039-2D2E0308-3D7F-4A2E-8708-1B78FF1646A2Q36169056-66C892B3-AE19-4B7D-9605-81B3E2DB0A88Q36194069-5CDA6206-4DF9-435A-A92C-0C8CDCD06AAAQ36233532-E0122869-B6E6-480E-A513-20762019E452Q36302865-56F11F0F-7AEB-4A44-8D03-4823D3BBCB44Q36316652-2A436418-048B-4E7C-8534-C864A16BA849Q36343596-BA92E409-72CD-4450-AFC6-1DE86941DCBAQ36438294-C25D90E2-207F-441B-ADE1-A68798464EE2Q36478849-A5B2840A-443A-4F2F-BFB8-B57ADFFDDBB5Q36617508-C5BA629E-7984-46AA-B620-EF0D07FF3B3CQ36649655-7BCB0B12-C6AC-4FCA-9449-B6A5B3985764Q36691274-281B6721-732E-4851-8788-C15EFB30BA54Q36893517-B6019965-0D9C-4BD2-88FD-95D5ED783FE4Q36918516-576601E7-562E-4787-B958-25679014EEC8Q37010620-3AC0A6FA-71D5-4A36-916D-90F472804F66Q37011370-F97296E8-3420-4C66-A76A-2680FE97371DQ37024725-59B4142B-294B-451D-B0C6-17F95F4DBAB0
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Progress in antisense technology.
@en
Progress in antisense technology.
@nl
type
label
Progress in antisense technology.
@en
Progress in antisense technology.
@nl
prefLabel
Progress in antisense technology.
@en
Progress in antisense technology.
@nl
P1476
Progress in antisense technology.
@en
P2093
Stanley T Crooke
P356
10.1146/ANNUREV.MED.55.091902.104408
P577
2004-01-01T00:00:00Z